Dexcom Inc (DXCM)
Health Care · Health Care Equipment · US stock · S&P 500 component
$86.04
▼ -1.67 (1.90%)
Day's range
$85.80 – $88.87
52-week range
$54.11 – $92.59
About Dexcom Inc
Dexcom develops and sells continuous glucose monitoring systems for people with diabetes. A small sensor worn on the body sends glucose readings to a smartphone or receiver, helping users and clinicians track levels without frequent finger pricks. Revenue comes from selling sensors and related hardware through pharmacies and distributors, and it depends on insurance coverage and reimbursement.
The company reported revenue of $5.0 billion for the last twelve months at Dexcom Inc. Revenue growth over the past three years averaged 17.0% a year. It kept an operating margin of 22.9%. The return on invested capital reached 59%, a measure of profit earned on the money invested in the business. The company does not pay a dividend. On the site's X-Ray Score, it rates 71 out of 100.
Written with AI from public information and the filing figures on this page, then checked automatically for unsupported numbers. It can contain mistakes: read the company's own filings below before relying on it.
Price chart
52-wk range $54.11 – $92.59Volume 3,583,400Daily, split-adjusted
Vitals
Market cap$33.6B
52-week range$54.11 – $92.59
Volume (last day)3,583,400
P/E (TTM)34.4
EBIT / EV yield3.5%
Free-cash-flow yield4.2%
Dividend yieldNo dividend
Revenue (TTM)$5.0B
Net income (TTM)$1,000M
Operating margin22.9%
Return on capital58.7%
Debt incl. leasesData missing
Cash & securities$1.1B
Debt = borrowings plus lease liabilities. Cash & securities = cash, equivalents and short-term marketable securities (long-term securities are not counted, so net cash can be understated for companies like Apple). Net debt = debt minus cash & securities. Source: latest SEC 10-Q/10-K. EBIT / EV yield = operating profit divided by market cap plus net debt.
Fair value estimate
Not rated
Debt not found in the filing data although interest is paid: not rated
What this means
Read the lenses below
A high score does not guarantee a good outcome; it shifts the odds a little. Use the checklist as a prompt for your own research.
Before you invest · decision checklist
Ticked boxes are filled in from our data; the rest are yours to answer.
The five-lens scan
Every score explained in one sentence, ranked against Health Care peers. Open a lens to see the numbers behind it.
Valuation
Weak
40/100
Expensive against its sector on earnings and cash flow.
See the numbers →
EBIT / EV yield3.5%
Free-cash-flow yield4.2%
Growth
Strong
87/100
Growing faster than most of its sector.
See the numbers →
Revenue growth (3y)17.0%
EPS growth (3y)36.6%
Growth consistency100%
Profitability
Strong
80/100
Earns high returns on the capital it uses.
See the numbers →
Return on invested capital58.7%
Operating margin22.9%
Gross profitability48.1%
Financial health
Strong
83/100
Balance sheet looks strong: debt is well covered.
See the numbers →
Piotroski F-Score8 / 9
Interest coverNo interest cost
Dividends
None
–/100
Pays no dividend.
See the numbers →
Quarterly results: last 6 quarters
+12.5%
Mar '25
+15.2%
Jun '25
+21.6%
Sep '25
+13.1%
Dec '25
+15.0%
Mar '26
+13.1%
Jun '26
Revenue against the same quarter a year earlier. Latest quarter revenue $1.3B, diluted EPS $0.64.
Compare with peers
RMD Resmed Inc73 PODD Insulet Corp69 IDXX Idexx Laboratories Inc67 STE STERIS plc64Other Health Care Equipment companies by X-Ray Score.
Fundamentals checklist
● 11 Good · ● 3 Average · ● 0 BadCash quality
Earnings backed by cashGood
Free-cash-flow yieldAverage
Risk models
Altman Z''Good
Piotroski F-ScoreGood
Growth
EPS growth (3y)Good
Free-cash-flow growth (3y)Good
Revenue growth (3y)Good
Growth consistencyGood
Balance sheet
Current ratioAverage
Interest coverGood
Valuation
EBIT / EV yieldAverage
Profitability
Return on invested capitalGood
Operating marginGood
Gross profitabilityGood
Each check is graded against the company's sector, not a fixed number. Checklist score 73/100.
Financials
| FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|
| Revenue | $2.4B | $2.9B | $3.6B | $4.0B | $4.7B |
| Operating income | $266M | $391M | $598M | $600M | $912M |
| Net income | $217M | $341M | $542M | $576M | $836M |
| Operating cash flow | $443M | $670M | $749M | $990M | $1.4B |
| Operating margin | 10.9% | 13.4% | 16.5% | 14.9% | 19.6% |
| Free cash flow | $53M | $305M | $512M | $631M | $1.1B |
| Diluted EPS | $0.53 | $0.82 | $1.30 | $1.42 | $2.09 |
Fiscal years, from SEC filings.
Technical summary
Daily
Bullish
8 bullish · 4 neutral · 4 bearish
Weekly
Strongly bullish
9 bullish · 1 neutral · 2 bearish
Monthly
Bullish
5 bullish · 1 neutral · 2 bearish
Moving averages (daily)
| SMA 10 | 85.13 | Bullish |
| EMA 10 | 85.58 | Bullish |
| SMA 20 | 86.15 | Bearish |
| EMA 20 | 85.87 | Bullish |
| SMA 50 | 87.55 | Bearish |
| EMA 50 | 85.00 | Bullish |
| SMA 100 | 80.86 | Bullish |
| EMA 100 | 81.38 | Bullish |
| SMA 200 | 73.97 | Bullish |
| EMA 200 | 77.42 | Bullish |
Oscillators (daily)
| RSI (14) | 50.26 | Neutral |
| MACD (12, 26) | -0.33 | Bearish |
| Momentum (12) | -0.29 | Bearish |
| Stochastic %K (14) | 52.91 | Neutral |
| Williams %R (14) | -47.09 | Neutral |
| CCI (20) | 37.48 | Neutral |
Pivot points (classic, last session)
S3 81.87 | S2 83.83 | S1 84.94 | Pivot 86.90 | R1 88.01 | R2 89.97 | R3 91.08 |
Signals describe what the chart is doing, not what to do. Moving averages: price above the average is bullish. Oscillators use the usual thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20; MACD and momentum above zero are bullish). Weekly and monthly views use closing prices only.
DXCM SEC filings
14 Sep 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
10 Sep 2026
8-KSEC EDGAR
Director or officer change; Regulation FD disclosure
30 Jul 2026
10-QSEC EDGAR
Quarterly report
30 Jul 2026
8-KSEC EDGAR
Results of operations
28 May 2026
8-KSEC EDGAR
Shareholder vote results
15 May 2026
8-KSEC EDGAR
Regulation FD disclosure; Other events
30 Apr 2026
10-QSEC EDGAR
Quarterly report
30 Apr 2026
8-KSEC EDGAR
Results of operations
Where the numbers come from
Statements SEC EDGAR filings (10-K, 10-Q), quarters derived from year-to-date figures.
Prices end-of-day closes, split-adjusted.
Industry inputs beta, multiples and equity risk premium from Damodaran Online (NYU Stern).
StocksXray is for education only and is not financial advice. Scores and fair values are model estimates from public filings and carry uncertainty.